This page has tags:

1. 1 2016-08-18T06:50:05-07:00 Ken Londoner 67400b6d41c00fbf11f194dad77d72364b87b2e2 Media Files Ken Londoner 3 Tag: Media Files vistag 2017-02-17T05:41:53-08:00 Ken Londoner 67400b6d41c00fbf11f194dad77d72364b87b2e2

This page is referenced by:

• 1 2016-08-18T06:29:44-07:00 Faster and More Convenient Diagnosis in Patients 1 plain 2016-08-18T06:29:45-07:00 With an increasingly aging U.S. population and rising rates of obesity, the frequency of cardiac arrhythmia is expected to increase significantly. The most common complex arrhythmia, Atrial fibrillation (AF), back in 2008 affected between 3 and 5 million people in the United States, and since then that number has increased to an alarming rate. Ken "Kenneth" Londoner, the co-founder BioSig Technologies, a privately held medical technology company, decided to invest in the rapidly growing electrophysiology marketplace and develop a new system for treating patients suffering from Atrial Fibrillation, more accurately.
  
  
  
  In order to confirm the diagnosis of AF and determine the most appropriate treatment, experts often use electrophysiology catheters, while cardiac ablation catheters are utilized to create lesions to prevent distribution of electrical signals that lead to certain arrhythmias. In the last few years, thanks to the improved technology used to diagnose arrhythmias, we have started to see an increase in the diagnosis of arrhythmias. In regards to that, Ken Londoner has been working on improvements, mainly in the form of wireless technology and software that allow faster and more convenient diagnosis in patients. With a 3-4% annual increase in the number of patients who need arrhythmia treatment, there has never been greater need for developing such devices.
  
  Thanks to his management and investments in this area of business, Kenneth Londoner was able to recognize the opportunity for profit in this industry.  If we consider the fact that in 2008 the electrophysiology and ablation devices market was valued at nearly $600 million, than we shouldn’t be too surprised of its current value, which adds up to an astonishing $4 billion. Intra-cardiac echocardiography diagnostic catheters is the fastest growing market segment within this market, as these devices are used more often in both ablation and interventional cardiology procedures. The recordings and analysis of the system are designed to help doctors in making clinical decisions in real-time by acquiring highly accurate cardiac signal recordings.
  
  Catheter ablation of ventricular tachycardia is perhaps one of the most complex challenges in interventional cardiology, and new technologies like that developed by BioSig and its founder are without a doubt needed and appreciated.